Cargando…
Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
BACKGROUND: The aim of the study was to assess the efficacy and safety of tofacitinib and its impact on quality of life in patients with moderate-to-severe ulcerative colitis. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials comparing tofacitinib with place...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102462/ https://www.ncbi.nlm.nih.gov/pubmed/30174394 http://dx.doi.org/10.20524/aog.2018.0276 |
_version_ | 1783349168684662784 |
---|---|
author | Paschos, Paschalis Katsoula, Anastasia Giouleme, Olga Sarigianni, Maria Liakos, Aris Athanasiadou, Eleni Bekiari, Eleni Tsapas, Apostolos |
author_facet | Paschos, Paschalis Katsoula, Anastasia Giouleme, Olga Sarigianni, Maria Liakos, Aris Athanasiadou, Eleni Bekiari, Eleni Tsapas, Apostolos |
author_sort | Paschos, Paschalis |
collection | PubMed |
description | BACKGROUND: The aim of the study was to assess the efficacy and safety of tofacitinib and its impact on quality of life in patients with moderate-to-severe ulcerative colitis. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials comparing tofacitinib with placebo or any active comparator. We searched Medline, Embase, the Cochrane Library and gray literature for articles published up to May 2017. We synthesized data using a fixed-effect model. We conducted subgroup analysis based on prior exposure to anti-tumor necrosis factor (TNF). We summarized the strength of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: We included three trials with 1220 participants. Compared with placebo, tofacitinib was effective in inducing clinical remission (odds ratio [OR] 3.84, 95% confidence interval [CI] 2.29-6.44, I(2:) 41%, GRADE: moderate), clinical response (OR 2.95, 95%CI 2.21-3.95, I(2:) 0%, GRADE: high), mucosal healing (OR 2.70, 95%CI 1.81-4.03, I(2:) 0%, GRADE: high). Tofacitinib was effective in both anti-TNF-naïve and -experienced patients. Tofacitinib had a favorable effect on quality of life. There were no significant differences in the safety profile in terms of the incidence of any or serious adverse events compared to placebo. The risk for infections was increased (OR 1.51, 95%CI 1.05-2.19, I(2:) 0%, GRADE: moderate), but the incidence of serious infections did not differ between tofacitinib and placebo. CONCLUSION: In patients with moderate-to-severe ulcerative colitis, short-term treatment with tofacitinib is effective for induction of remission and improvement of quality of life. |
format | Online Article Text |
id | pubmed-6102462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hellenic Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-61024622018-09-01 Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis Paschos, Paschalis Katsoula, Anastasia Giouleme, Olga Sarigianni, Maria Liakos, Aris Athanasiadou, Eleni Bekiari, Eleni Tsapas, Apostolos Ann Gastroenterol Original Article BACKGROUND: The aim of the study was to assess the efficacy and safety of tofacitinib and its impact on quality of life in patients with moderate-to-severe ulcerative colitis. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials comparing tofacitinib with placebo or any active comparator. We searched Medline, Embase, the Cochrane Library and gray literature for articles published up to May 2017. We synthesized data using a fixed-effect model. We conducted subgroup analysis based on prior exposure to anti-tumor necrosis factor (TNF). We summarized the strength of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: We included three trials with 1220 participants. Compared with placebo, tofacitinib was effective in inducing clinical remission (odds ratio [OR] 3.84, 95% confidence interval [CI] 2.29-6.44, I(2:) 41%, GRADE: moderate), clinical response (OR 2.95, 95%CI 2.21-3.95, I(2:) 0%, GRADE: high), mucosal healing (OR 2.70, 95%CI 1.81-4.03, I(2:) 0%, GRADE: high). Tofacitinib was effective in both anti-TNF-naïve and -experienced patients. Tofacitinib had a favorable effect on quality of life. There were no significant differences in the safety profile in terms of the incidence of any or serious adverse events compared to placebo. The risk for infections was increased (OR 1.51, 95%CI 1.05-2.19, I(2:) 0%, GRADE: moderate), but the incidence of serious infections did not differ between tofacitinib and placebo. CONCLUSION: In patients with moderate-to-severe ulcerative colitis, short-term treatment with tofacitinib is effective for induction of remission and improvement of quality of life. Hellenic Society of Gastroenterology 2018 2018-05-10 /pmc/articles/PMC6102462/ /pubmed/30174394 http://dx.doi.org/10.20524/aog.2018.0276 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Paschos, Paschalis Katsoula, Anastasia Giouleme, Olga Sarigianni, Maria Liakos, Aris Athanasiadou, Eleni Bekiari, Eleni Tsapas, Apostolos Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis |
title | Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis |
title_full | Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis |
title_fullStr | Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis |
title_full_unstemmed | Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis |
title_short | Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis |
title_sort | tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102462/ https://www.ncbi.nlm.nih.gov/pubmed/30174394 http://dx.doi.org/10.20524/aog.2018.0276 |
work_keys_str_mv | AT paschospaschalis tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis AT katsoulaanastasia tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis AT gioulemeolga tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis AT sarigiannimaria tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis AT liakosaris tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis AT athanasiadoueleni tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis AT bekiarieleni tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis AT tsapasapostolos tofacitinibforinductionofremissioninulcerativecolitissystematicreviewandmetaanalysis |